Tandem Diabetes Care (NASDAQ:TNDM) Advances 4.7% This Week, Taking One-year Gains to 115%
Tandem Diabetes Care Is Maintained at Equal-Weight by Morgan Stanley
TNDM Stock Likely to Gain From Innovation Amid Competition
Why Tandem Diabetes Care Stock Thrashed the Market Today
Sector Update: Health Care Stocks Rise in Late Afternoon Trading
Sector Update: Health Care
Tandem Diabetes Rises as Insulin Pump Cleared for Use in EU With Lilly Insulin
Tandem T:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-rapid Acting Insulin in European Union
Three 'Buys,' Three 'Sells,' and a 'Hold,' by Oppenheimer Analysts
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Conflicted on These Healthcare Names: Sanofi (OtherSNYNF) and Tandem Diabetes Care (TNDM)
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Doing What It Can To Lift Shares
Tandem Diabetes Care Announces Upcoming Conference Participation
Tandem Diabetes a New Equal Weight at Morgan Stanley Due to Competition
Morgan Stanley Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $45
Express News | Morgan Stanley Initiates Coverage On Tandem Diabetes Care With Equal-Weight Rating, Announces Price Target of $45
Tandem Diabetes Care Analyst Ratings
Lake Street Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $75
Lake Street Sticks to Its Buy Rating for Tandem Diabetes Care (TNDM)